Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

December 06, 2023 00:21:48
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
COR2ED - Oncology Medical Conversation
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

Dec 06 2023 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode

December 06, 2023 00:25:10
Episode Cover

Cáncer de próstata: Inhibidores de PARP - lo que las enfermeras necesitan saber

COR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en el Hospital Universitario Virgen...

Listen

Episode

December 06, 2023 00:30:42
Episode Cover

HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment...

Listen

Episode

December 06, 2023 00:19:56
Episode Cover

Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on...

Listen